Analytical Data
-
Gene name
PON1
- Application
-
Alternative Names
PON1；PON；Serum paraoxonase/arylesterase 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P27169
-
Expression Region
1-355aa
-
AA Sequence
MAKLIALTLLGMGLALFRNHQSSYQTRLNALREVQPVELPNCNLVKGIET GSEDLEILPNGLAFISSGLKYPGIKSFNPNSPGKILLMDLNEEDPTVLEL GITGSKFDVSSFNPHGISTFTDEDNAMYLLVVNHPDAKSTVELFKFQEEE KSLLHLKTIRHKLLPNLNDIVAVGPEHFYGTNDHYFLDPYLQSWEMYLGL AWSYVVYYSPSEVRVVAEGFDFANGINISPDGKYVYIAELLAHKIHVYEK HANWTLTPLKSLDFNTLVDNISVDPETGDLWVGCHPNGMKIFFYDSENPP ASEVLRIQNILTEEPKVTQVYAENGTVLQGSTVASVYKGKLLIGTVFHKA LYCEL
-
Molecular Weight
41 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PON1, or paraoxonase 1, is an important enzyme primarily associated with high-density lipoprotein (HDL) in the bloodstream. It has garnered significant attention in research due to its role in detoxifying organophosphates, reducing oxidative stress, and modulating inflammation. Dysregulation of PON1 has been implicated in various diseases, including cardiovascular disorders and Alzheimer's disease, which has prompted extensive studies on its biochemical properties and physiological functions. The recombinant production of PON1 allows for detailed investigation of its structure-function relationships and potential therapeutic applications. By utilizing genetic engineering techniques, researchers can obtain large quantities of active PON1 for in vitro and in vivo studies, facilitating the exploration of its mechanisms in lipid metabolism and its protective roles against oxidative damage. Furthermore, insights gained from these studies could lead to the development of novel treatments aimed at enhancing PON1 activity or mimicking its beneficial effects, thereby contributing to better health outcomes in conditions associated with its dysfunction. As such, PON1 recombinant protein represents a promising avenue for advancing our understanding of this critical enzyme and leveraging its properties for clinical applications.
